PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66588-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)66588-6/fulltext
Section Title :
Section Order :
423
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66588-6&doi=10.1016/S1098-3015(10)66588-6